EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulator... ( October 25 2007 (Providence RI)--- EpiV...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulatory' T-cells

Date:10/25/2007

October 25, 2007 (Providence, RI)--- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the worlds largest charitable funder of Type 1 diabetes research, to develop Epi-13, a novel therapeutic for the prevention and treatment of type I diabetes, a devastating and chronic autoimmune disease that affects up to three million Americans today.

JDRF will provide EpiVax $351,000 for one year to provide a first proof-of-principle for the drug that will focus on the natural regulatory T cells and their protective role in the diabetes patient. The studies are anticipated to show that the drug reduces harmful immune responses to insulin-producing cells, preserving the bodys ability to make its own insulin.

JDRFs research funding provides an exciting opportunity to accelerate the proof of concept and commercial development of an immune-based therapy for Type 1 diabetes, said Anne De Groot, M.D., President and CEO of EpiVax. We hope to make it possible for persons living with diabetes to reduce insulin dependence and to live longer with fewer symptoms.

As antigen specific tolerance continues to be a major goal area in Autoimmunity for JDRF, the proposal from EpiVax presents a novel approach that could potentially generate or restore immune regulation in type 1 diabetes, said Teodora Staeva-Vieira, Ph.D., Director of the Autoimmunity Program at JDRF.

JDRF funds diabetes research across a range of scientific areas, including autoimmunity, regeneration, islet cell replacement, complications, and metabolic control. The agreement with EpiVax is a part of JDRFs innovative Industry Discovery and Development Partnership program, through which JDRF partners with pharmaceutical, biotech, and medical device businesses who are looking to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1
'/>"/>

Contact: Susan Sherman
ssherman@jdrf.org
212-479-7510
Juvenile Diabetes Research Foundation International
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Pitt study suggests craving hinders comprehension without your realizing it 2 Health News:Lilly Announces the First 300-unit Vial of Insulin 2 Health News:Lilly Announces the First 300-unit Vial of Insulin 3 Health News:Lilly Announces the First 300-unit Vial of Insulin 4 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5 Health News:Pitt study suggests craving hinders comprehension without you realizing it 2 Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2 Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3

[0] Pitt study suggests craving hinders comprehension without your realizing it [0] Lilly Announces the First 300-unit Vial of Insulin [0] Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management [0] Pitt study suggests craving hinders comprehension without you realizing it [1] Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange

Julie L. Novak Named Executive Director of Michigan State Medical Society Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 National Health Care Coalition Commends New Congress' Focus on Fighting Chronic Disease in House Stimulus Package Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009 Optelec and ShopLowVision.com Bring Life Back Into Focus at ATIA 2009 Orlando Patients' Bath Basins Increase Risk for Hospital-Acquired Infections

Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2 The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2 The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3 The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4 The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 Weight Loss Surgery Breaks Families Obesity Cycle 55987 1 Weight Loss Surgery Breaks Families Obesity Cycle 55987 2 Dr William J Robbins Joins Anpath Group Inc Board of Directors 55984 1 Dr William J Robbins Joins Anpath Group Inc Board of Directors 55984 2 Dr William J Robbins Joins Anpath Group Inc Board of Directors 55984 3 Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 1 Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 2 Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 3

[0] Hill-Rom Announces Appointment of James R. Giertz to Board of Directors [0] The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program

Other Medicine Technology:VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2 VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3 VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4 VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5 VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6 New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2 New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3 New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4 New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5 New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Medicine Products:

BioPlex® 2200 HSV Non-Typing ASR ImmuLisa Anti-Myeloperoxidase MPO (pANCA)DiffSpin 2

EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulator...( October 25 2007 (Providence RI)--- EpiV...),Health